Compare Cytokinetics Inc (CYTK) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs MasTec Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while MasTec Inc trades at $219.65 (market cap $17.40B). The key difference: MasTec Inc is far larger — about 2× Cytokinetics Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and MasTec Inc for 23 Days on average.
| CYTK | MTZ | |
|---|---|---|
Market Cap | $8.62B | $17.40B |
Volume | 2,594,626 | 1,415,821 |
Sector | Health | Industrials |
52-Week High | $87.26 | $437.51 |
52-Week Low | $54.76 | $190.08 |
Typical Hold Time | 19 Days | 23 Days |
Enterprise Value | $8.72B | $20.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
MasTec (MTZ) trades at $223.37, down 2.16% on the day, with technical indicators showing a neutral to bearish short-term bias. The company demonstrates strong fundamentals with Q1 2026 earnings beating expectations and a robust 88.9% analyst buy rating. Recent news highlights MTZ's positioning to benefit from infrastructure investment cycles, particularly in power delivery and data center markets, supported by a record $21.4 billion backlog.
The outlook remains positive given strong institutional support and infrastructure tailwinds, though premium valuation and communications segment softness pose risks. With a consensus price target of $408.58 representing 83% upside potential, the stock offers significant growth opportunity for investors comfortable with execution risks in the competitive infrastructure sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
